Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

French drugmaker Sanofi SA is reviewing operations at two of its vaccine making facilities in India and plans to let go of all employees at the plants, the company told Reuters, after it failed to win a UNICEF contract.

Exclusive: Sanofi to let go of staff at vaccine plants in India as part of review

Regeneron Pharmaceuticals

Dupixent ® (dupilumab) approved by European Commission as the first and only targeted medicine indicat ed for eosinophilic esophagitis

Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis

This vaccine candidate could be approved in newborns and infants later this year.

Could This Vaccine Become Sanofi's Latest Blockbuster?

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.15% gained about 2.5% in premarket trading on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi SAN, -0.37% SNY, -0.16% , for children as young as six months old. European regulators are expected to make a final decision in the coming months.

Regeneron, Sanofi's Dupixent is one step closer to approval for young children in Europe

AstraZeneca

BioNTech SE

CVS Health

Gilead Sciences

LHC Group

Leap Therapeutics

Moderna

Neovasc

Signify Health

Shockwave Medical

UnitedHealth Group

Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).

Mergers and Acquisitions in 2023 Off To A Strong Start

Dupixent ® (dupilumab) r ecommended for expanded EU a pproval by the CHMP to t reat c hildren as young as six months old with s evere a topic d ermatitis

Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

Dominion Energy

Diageo

Enterprise Products Partners

JD.com

Philip Morris

Sonoco Products

Buying blue-chip stocks is generally a smart decision. They tend to be established, profitable, name-brand companies marked by reliable growth.

7 Blue-Chip Stocks to Buy as a New Bull Market Emerges

NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

Elevance Health Inc

It's difficult to imagine a future where healthcare isn't in high demand.

Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023

PARIS , Jan. 18, 2023 /PRNewswire/ -- Sanofi announces at the 53rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher education scholarship program for people from numerous communities underrepresented in healthcare professions. The program will help pay tuition and other expenses at institutions of higher education for students who are part of their nation's ethnic minority groups, women, people with disabilities and members of the LGBTQ+ community who wish to pursue careers as doctors, nurses, scientists, researchers and other healthcare-related professions.

Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare

Novo Nordisk

SNY vs. NVO: Which Stock Is the Better Value Option?

Eli Lilly

The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.

State of California Sues Insulin Makers for Unfair Practices

Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Sanofi SA (NASDAQ:SNY ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 1:30 PM ET Company Participants Paul Hudson - CEO Conference Call Participants Richard Vosser - JPMorgan Richard Vosser Welcome to the Sanofi presentation at the 41st JPMorgan Healthcare Conference.

Sanofi SA (SNY) CEO Paul Hudson Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Bayer AG

CAMBRIDGE, Mass. & LEVERKUSEN, Germany--( BUSINESS WIRE )--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

AbbVie

Amgen

Bristol-Myers

Johnson & Johnson

Merck

Novartis

Pfizer

Roche Holding AG

The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.

Ranking The Top 10 Pharmaceuticals By Pipeline

This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.

What This Drug News Could Mean for Sanofi Shareholders

FDA accepts nirsevimab application as first protective option against RSV disease for all infants

Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants

Availability of the Q4 Memorandum for modelling purposes

Press Release: Availability of the Q4 2022 Memorandum for modelling purposes

GlaxoSmithKline

Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.

3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

Medtronic

Medical Properties Trust

These three offer high dividend yields and consistent revenue growth.

3 Medical Dividend Stocks That Hit the Sweet Spot

P ositive Dupixent ® (dupilumab) P hase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Sanofi's SARS-CoV-2 spike protein (B.1.351 strain) vaccine, (VidPrevtyn® Beta) is the first and only Beta variant protein-based COVID-19 booster approved in Great Britain and the European Union

MHRA authorises VidPrevtyn® Beta▼ in Great Britain, Sanofi's COVID-19 booster vaccine

With economic worries unsettling investors, it is not surprising that leading advisors, and contributors to MoneyShow.com, are looking to the pharmaceutical sector – Here's a look at seven global favorites, focused on such areas as obesity and diabetes to new applications for mRNA-based vaccines.

News for Sanofi Stock (SNY)